SLX-3065 / Biolexis Therap - LARVOL DELTA

Discovery of an oral, potent, and selective CDK9 molecular glue degrader SLX-3065 active in aggressive variant prostate cancers (AVPC) (AACR 2024) - "Kinase selectivity, Nano BRET, ADME-Tox, in vitro safety, secondary pharmacological assays, Cell engraftment mouse tumor mode, and PK studies were performed. We designed and synthesized a series of novel small molecule CDK9 Molecular Glue degraders based on our initial CDK9 inhibitor lead SLX-3030 and SLX-3039. In summary, both SLX-3064 and SLX-3065 molecular glues display complete degradation of CDK9 and its downstream markers, and these degraders possess ideal developable criteria as oral agents. With these characteristics, SLX-3065 was selected as a candidate that had the appropriate developable properties and our plans for conducting additional IND-enabling studies and future clinical trial plans will also be discussed."

Late-breaking abstract • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • CDK9 • MCL1 • MYC • MYCN

Biolexis Therapeutics to Present Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PRNewswire) - "Biolexis Therapeutics, Inc...today announced it will present five posters at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA."

Preclinical • Genito-urinary Cancer • Hematological Malignancies • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor